This chapter explores the potential inequalities in accessing treatments for long COVID in low-income nations and highlights the difficulties faced by healthcare systems in providing intensive monitoring and care.
Evidence so far suggests that the prevalence of long COVID in low- and middle-income countries could be similar to that of wealthier countries. For example, by some estimates, more than four million people in Brazil have long COVID.
However, an absence of research on the condition in less-wealthy countries has left advocates hamstrung: few physicians acknowledge that long COVID exists. A lack of data is also hampering efforts to search for the mechanisms of the condition and tailor treatments.